Fusion Pharmaceuticals (FUSN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

FUSN Stock Forecast


Fusion Pharmaceuticals stock forecast is as follows: an average price target of $15.25 (represents a -29.23% downside from FUSN’s last price of $21.55) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.

FUSN Price Target


The average price target for Fusion Pharmaceuticals (FUSN) is $15.25 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $6.00. This represents a potential -29.23% downside from FUSN's last price of $21.55.

FUSN Analyst Ratings


Hold

According to 11 Wall Street analysts, Fusion Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for FUSN stock is 2 'Strong Buy' (18.18%), 2 'Buy' (18.18%), 6 'Hold' (54.55%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).

Fusion Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 19, 2024Matthew HarrisonMorgan Stanley$21.00$21.18-0.85%-2.55%
Mar 19, 2024Suji JeongJefferies$21.00$21.18-0.85%-2.55%
Sep 29, 2023Jeff JonesOppenheimer$13.00$2.60400.00%-39.68%
Nov 30, 2022-Leerink Partners$6.00$2.16177.78%-72.16%
Row per page
Go to

The latest Fusion Pharmaceuticals stock forecast, released on Mar 19, 2024 by Matthew Harrison from Morgan Stanley, set a price target of $21.00, which represents a -0.85% decrease from the stock price at the time of the forecast ($21.18), and a -2.55% decrease from FUSN last price ($21.55).

Fusion Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$21.00
Last Closing Price$21.55$21.55$21.55
Upside/Downside-100.00%-100.00%-2.55%

In the current month, the average price target of Fusion Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fusion Pharmaceuticals's last price of $21.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Apr 16, 2024Cowen & Co.-HoldDowngrade
Mar 20, 2024WedbushSector PerformSector PerformHold
Mar 19, 2024Leerink Partners-Market PerformDowngrade
Mar 04, 2024WedbushStrong BuyStrong BuyHold
Jan 26, 2024WedbushStrong BuyStrong BuyHold
Dec 27, 2023Raymond JamesOutperformStrong BuyUpgrade
Dec 27, 2023RBC CapitalStrong BuyStrong BuyHold
Jun 23, 2023B. Riley Securities-NeutralInitialise
Jun 23, 2023Compass Point-SellInitialise
Jun 23, 2023Piper Sandler-NeutralInitialise
Row per page
Go to

Fusion Pharmaceuticals's last stock rating was published by Cowen & Co. on Apr 16, 2024. The company Downgrade its FUSN rating from "null" to "Hold".

Fusion Pharmaceuticals Financial Forecast


Fusion Pharmaceuticals Revenue Forecast

Dec 27Oct 27Jul 27Mar 27Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Oct 21Dec 20
Revenue-------------------$28.00K$140.00K--$585.00K--
Avg Forecast$1.79M$597.70K----------$193.50K$186.00K$192.67K$168.50K$412.40K$86.00K$75.00K$8.57M$17.00K$100.00K$137.50K$1.42M$260.50K$3.33M
High Forecast$1.79M$597.70K----------$193.50K$186.00K$192.67K$168.75K$793.08K$86.00K$75.00K$8.57M$17.00K$100.00K$137.50K$1.42M$260.50K$3.33M
Low Forecast$1.79M$597.70K----------$193.50K$186.00K$192.67K$168.25K$31.72K$86.00K$75.00K$8.57M$17.00K$100.00K$137.50K$1.42M$260.50K$3.33M
# Analysts11----------11236444222234
Surprise %-------------------0.00%8.24%--0.41%--

Fusion Pharmaceuticals's average Quarter revenue forecast for Jul 23 based on 4 analysts is $75.00K, with a low forecast of $75.00K, and a high forecast of $75.00K. FUSN's average Quarter revenue forecast represents a 167.86% increase compared to the company's last Quarter revenue of $28.00K (Mar 23).

Fusion Pharmaceuticals EBITDA Forecast

Dec 27Oct 27Jul 27Mar 27Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Oct 21Dec 20
# Analysts11----------11236444222234
EBITDA----------------$-27.91M--$-23.08M$-23.79M--$-20.32M--
Avg Forecast$-358.62K$-119.54K----------$-38.70K$-37.20K$-38.53K$-33.70K$-82.48K$-17.20K$-15.00K$-1.71M$-3.40K$-20.00K$-27.50K$-20.50M$-52.10K$-666.67K
High Forecast$-358.62K$-119.54K----------$-38.70K$-37.20K$-38.53K$-33.65K$-6.34K$-17.20K$-15.00K$-1.71M$-3.40K$-20.00K$-27.50K$-16.40M$-52.10K$-666.67K
Low Forecast$-358.62K$-119.54K----------$-38.70K$-37.20K$-38.53K$-33.75K$-158.62K$-17.20K$-15.00K$-1.71M$-3.40K$-20.00K$-27.50K$-24.60M$-52.10K$-666.67K
Surprise %----------------338.44%--13.46%6998.53%--0.99%--

undefined analysts predict FUSN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fusion Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Fusion Pharmaceuticals Net Income Forecast

Dec 27Oct 27Jul 27Mar 27Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Oct 21Dec 20
# Analysts11----------11236444222234
Net Income----------------$-28.18M--$-24.29M$-24.62M--$-19.91M--
Avg Forecast$-47.38M$-45.85M$-41.29M$-36.24M$-35.86M$-35.30M$-34.74M$-34.94M$-37.41M$-36.70M$-34.72M$-34.33M$-30.26M$-30.28M$-29.53M$-31.11M$-28.40M$-33.52M$-32.92M$-25.96M$-45.94M$-41.99M$-43.40M$-20.74M$-48.42M$-15.50M
High Forecast$-47.38M$-45.85M$-41.29M$-36.24M$-35.86M$-35.30M$-34.74M$-34.94M$-37.41M$-36.70M$-34.72M$-34.33M$-30.26M$-30.28M$-22.35M$-31.11M$-22.56M$-33.52M$-32.92M$-25.96M$-45.94M$-41.99M$-43.40M$-16.59M$-48.42M$-15.50M
Low Forecast$-47.38M$-45.85M$-41.29M$-36.24M$-35.86M$-35.30M$-34.74M$-34.94M$-37.41M$-36.70M$-34.72M$-34.33M$-30.26M$-30.28M$-35.12M$-31.11M$-35.09M$-33.52M$-32.92M$-25.96M$-45.94M$-41.99M$-43.40M$-24.89M$-48.42M$-15.50M
Surprise %----------------0.99%--0.94%0.54%--0.96%--

Fusion Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FUSN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Fusion Pharmaceuticals SG&A Forecast

Dec 27Oct 27Jul 27Mar 27Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Oct 21Dec 20
# Analysts11----------11236444222234
SG&A----------------$7.63M--$9.01M$6.95M--$8.45M--
Avg Forecast$20.39M$6.80M----------$2.20M$2.11M$2.19M$1.92M$4.69M$977.79K$852.72K$97.45M$193.28K$1.14M$1.56M$16.12M$2.96M$37.90M
High Forecast$20.39M$6.80M----------$2.20M$2.11M$2.19M$1.92M$9.02M$977.79K$852.72K$97.45M$193.28K$1.14M$1.56M$16.12M$2.96M$37.90M
Low Forecast$20.39M$6.80M----------$2.20M$2.11M$2.19M$1.91M$360.68K$977.79K$852.72K$97.45M$193.28K$1.14M$1.56M$16.12M$2.96M$37.90M
Surprise %----------------1.63%--0.09%35.96%--0.52%--

Fusion Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $1.92M, based on 3 Wall Street analysts, with a range of $1.91M to $1.92M. The forecast indicates a -74.88% fall compared to FUSN last annual SG&A of $7.63M (Dec 23).

Fusion Pharmaceuticals EPS Forecast

Dec 27Oct 27Jul 27Mar 27Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Oct 21Dec 20
# Analysts11----------11236444222234
EPS----------------$-0.39--$-0.45$-0.55--$-0.46-$-0.32
Avg Forecast$-0.57$-0.55$-0.49$-0.43$-0.43$-0.42$-0.41$-0.42$-0.45$-0.44$-0.41$-0.41$-0.36$-0.36$-0.35$-0.37$-0.34$-0.40$-0.39$-0.31$-0.55$-0.50$-0.52$-0.44$-0.58$-0.18
High Forecast$-0.57$-0.55$-0.49$-0.43$-0.43$-0.42$-0.41$-0.42$-0.45$-0.44$-0.41$-0.41$-0.36$-0.36$-0.27$-0.37$-0.27$-0.40$-0.39$-0.31$-0.55$-0.50$-0.52$-0.44$-0.58$-0.18
Low Forecast$-0.57$-0.55$-0.49$-0.43$-0.43$-0.42$-0.41$-0.42$-0.45$-0.44$-0.41$-0.41$-0.36$-0.36$-0.42$-0.37$-0.42$-0.40$-0.39$-0.31$-0.55$-0.50$-0.52$-0.44$-0.58$-0.18
Surprise %----------------1.15%--1.45%1.00%--1.04%-1.73%

According to undefined Wall Street analysts, Fusion Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FUSN previous annual EPS of $NaN (undefined).

Fusion Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
RAPTRAPT Therapeutics$1.05$30.712824.76%Hold
PMVPPMV Pharmaceuticals$1.61$18.001018.01%Buy
PASGPassage Bio$0.54$6.001011.11%Buy
SPROSpero Therapeutics$1.19$10.00740.34%Buy
CHRSCoherus BioSciences$1.10$9.00718.18%Hold
OLMAOlema Pharmaceuticals$7.87$28.50262.13%Buy
BCABBioAtla$1.39$5.00259.71%Buy
FENCFennec Pharmaceuticals$4.72$15.75233.69%Buy
BCYCBicycle Therapeutics$20.26$54.40168.51%Buy
RLMDRelmada Therapeutics$2.75$5.67106.18%Buy
KROSKeros Therapeutics$53.84$102.6090.56%Buy
NAMSNewAmsterdam Pharma Company$20.12$36.5081.41%Buy
BOLTBolt Biotherapeutics$0.57$1.0075.44%Hold
HRMYHarmony Biosciences$33.23$48.8647.04%Buy
EWTXEdgewise Therapeutics$31.98$45.0040.71%Buy
JANXJanux Therapeutics$46.50$61.2031.61%Buy
IKNAIkena Oncology$1.73$1.33-23.12%Buy
FUSNFusion Pharmaceuticals$21.55$15.25-29.23%Hold
GRCLGracell Bio$10.25$6.00-41.46%Buy

FUSN Forecast FAQ


Is Fusion Pharmaceuticals a good buy?

No, according to 11 Wall Street analysts, Fusion Pharmaceuticals (FUSN) is considered a 'Hold'. The rating consensus is based on 2 'Strong Buy' and 2 'Buy' recommendations, accounting for 36.36% of FUSN's total ratings.

What is FUSN's price target?

Fusion Pharmaceuticals (FUSN) average price target is $15.25 with a range of $6 to $21, implying a -29.23% from its last price of $21.55. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Fusion Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for FUSN stock, the company can go down by -29.23% (from the last price of $21.55 to the average price target of $15.25), down by -2.55% based on the highest stock price target, and down by -72.16% based on the lowest stock price target.

Can Fusion Pharmaceuticals stock reach $30?

FUSN's average twelve months analyst stock price target of $15.25 does not support the claim that Fusion Pharmaceuticals can reach $30 in the near future.

What are Fusion Pharmaceuticals's analysts' financial forecasts?

Fusion Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-141M (high $-141M, low $-141M), average SG&A $0 (high $0, low $0), and average EPS is $-1.681 (high $-1.681, low $-1.681). FUSN's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $2.39M (high $2.39M, low $2.39M), average EBITDA is $-478K (high $-478K, low $-478K), average net income is $-171M (high $-171M, low $-171M), average SG&A $27.18M (high $27.18M, low $27.18M), and average EPS is $-2.038 (high $-2.038, low $-2.038).

Did the FUSN's actual financial results beat the analysts' financial forecasts?

Based on Fusion Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $2.07M, which missed the average analysts forecast of $9.14M by -77.39%. Apple's EBITDA was $-99.232M, beating the average prediction of $-1.829M by 5325.59%. The company's net income was $-94.897M, missing the average estimation of $-121M by -21.45%. Apple's SG&A was $31.2M, missing the average forecast of $103.97M by -70.00%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-1.442 by -99.90%. In terms of the last quarterly report (Mar 2023), Fusion Pharmaceuticals's revenue was $28K, missing the average analysts' forecast of $8.57M by -99.67%. The company's EBITDA was $-23.079M, beating the average prediction of $-1.714M by 1246.28%. Fusion Pharmaceuticals's net income was $-24.291M, missing the average estimation of $-25.963M by -6.44%. The company's SG&A was $9.01M, missing the average forecast of $97.45M by -90.76%. Lastly, the company's EPS was $-0.45, beating the average prediction of $-0.31 by 45.20%